中国二级和三级医院具有抗菌效果的中成药使用及费用变化趋势: 2011–2015年药品采购数据分析

doi:10.5246/jcps.2022.04.0275

中国药学(英文版) ›› 2022, Vol. 31 ›› Issue (4): 298-307.DOI: 10.5246/jcps.2022.04.0275

• 【药事管理与临床药学专栏】 • 上一篇下一篇

中国二级和三级医院具有抗菌效果的中成药使用及费用变化趋势: 2011–2015年药品采购数据分析

玉米提·塔西甫拉提¹^,^#, 周越¹^,^#, 韩晟¹^,², 杜可欣¹, 杨瑶瑶¹, 胡琳¹, 郑波³, 管晓东¹^,², 海沙尔江·吾守尔¹^,²^,^*(), 史录文¹^,²^,^*()

1. 北京大学药学院药事管理与临床药学系, 北京 100191
2. 北京大学医药管理国际研究中心, 北京 100191
3. 北京大学第一医院临床药理研究所, 北京 100034

收稿日期:2021-11-10 修回日期:2021-11-23 接受日期:2021-12-05 出版日期:2022-04-30 发布日期:2022-04-30
通讯作者: 海沙尔江·吾守尔, 史录文
作者简介:
+ Tel./Fax: +86-10-82805019, E-mail: shilu@bjmu.edu.cn
+ E-mail: kaiser@bjmu.edu.cn
基金资助:
National Natural Science Foundation of China (Grant No. 81973294, 81861138048 and 71774005) and China Medical Board (Grant No. 17-270).

Trends of consumption and expenditure of antibacterial traditional Chinese medicine in secondary and tertiary hospitals in China: an analysis of pharmaceutical sales data, 2011–2015

Yumiti Taxifulati¹^,^#, Yue Zhou¹^,^#, Sheng Han¹^,², Kexin Du¹, Yaoyao Yang¹, Lin Hu¹, Bo Zheng³, Xiaodong Guan¹^,², Haishaerjiang Wushouer¹^,²^,^*(), Luwen Shi¹^,²^,^*()

1 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2 International Research Centre for Medicinal Administration (IRCMA), Peking University Health Science Center, Beijing 100191, China
3 Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100034, China

Received:2021-11-10 Revised:2021-11-23 Accepted:2021-12-05 Online:2022-04-30 Published:2022-04-30
Contact: Haishaerjiang Wushouer, Luwen Shi
About author:
# Yumiti Taxifulati and Yue Zhou contributed equally to this work.

摘要/Abstract

摘要：

中成药在中国被普遍使用, 其中一些中成药已被证明对特定的致病菌引起的感染有效。本研究旨在利用2011年1月至2015年12月的药品采购数据, 描述中国二级和三级医院具有抗菌效果的中成药的使用和费用变化趋势。本文回顾性地分析了中国医院具有抗菌作用的中成药月度采购监测数据。采用人口加权的每日限定日剂量, 即基于药品说明书中推荐的剂量方案的每日推荐量。具有抗菌效果的中成药的使用量以每1000人/天的DDD表示(DID)。具有抗菌效果的中成药费用以美元表示。使用复合年均增长率(CAGR)来描述具有抗菌效果的中成药的使用量和费用的增长。对来自28个省的468家三级医院和114家二级医院的1293种具有抗菌效果的中成药进行了匹配和分析。在研究期间, 具有抗菌效果的中成药的使用量和费用总体表现出明显的上升趋势, 使用量从4.07 DID到6.82 DID, 年均复合增长率为13.75%; 费用从8.3975亿美元到12.7682亿美元, 年均复合增长率为11.04%。与东部省份相比, 中部和西部省份具有抗菌效果的中成药的消费量更高。肠外用药占具有抗菌效果的中成药总消耗量的7.20%, 但占总费用的近45%。中国具有抗菌效果的中成药的使用快速增长, 这可能是抗菌药物管理的替代效应, 但存在随之而来的过度使用的潜在风险。需要更多的研究来进一步探索具有抗菌效果的中成药的潜在疗效, 使其成为感染治疗的替代方法, 并帮助遏制细菌耐药。

关键词: 抗菌作用, 中成药, 药物使用, 药物费用

Abstract:

Traditional Chinese medicines (TCMs) are commonly used in China, and some of them have been proved to be effective against infection caused by certain pathogenic bacteria. In the present study, we aimed to describe the trends of antibacterial-effect traditional Chinese medicine (AeTCM) consumption and expenditure in secondary and tertiary hospitals in China using pharmaceutical sales data from January 2011 to December 2015. Aggregated monthly surveillance data on AeTCM sales in China’s hospitals were retrospectively analyzed. Population weighted daily define doses, which are the recommended daily amounts based on dosage regimen recommended in the manufacturers’ instructions, were adopted. The AeTCM consumption was expressed in DDD per 1000 inhabitants per day (DID). The AeTCM expenditure was expressed in US dollars. A compound annual growth rate (CAGR) was used to describe the growth of AeTCM consumption and expenditure. A total of 1293 AeTCMs were matched and analyzed from 468 tertiary hospitals and 114 secondary hospitals from 28 provinces. The total AeTCM consumption and expenditure demonstrated a significant upward trend during the study period from 4.07 DID to 6.82 DID with a CAGR of 13.75%, and 839.75 million US dollars to 1276.82 million US dollars with a CAGR of 11.04%, respectively. Compared with eastern provinces, the consumption of AeTCMs was higher in the central and western provinces. Parenteral AeTCMs accounted for 7.20% of the total AeTCM consumption, but nearly 45% of the total AeTCM expenditure. The AeTCM use in China demonstrated a rapid growth, which could be the result of the substitutional effect from antimicrobial stewardship and brought a potential risk of overuse. More studies are needed to further explore the potential efficacy of AeTCMs as an alternative approach towards infection treatment and to help confine antimicrobial resistance.

Key words: Antibacterial-effect, Traditional Chinese medicine, Drug consumption, Drug expenditure

Supporting:

玉米提·塔西甫拉提, 周越, 韩晟, 杜可欣, 杨瑶瑶, 胡琳, 郑波, 管晓东, 海沙尔江·吾守尔, 史录文. 中国二级和三级医院具有抗菌效果的中成药使用及费用变化趋势: 2011–2015年药品采购数据分析[J]. 中国药学(英文版), 2022, 31(4): 298-307.

Yumiti Taxifulati, Yue Zhou, Sheng Han, Kexin Du, Yaoyao Yang, Lin Hu, Bo Zheng, Xiaodong Guan, Haishaerjiang Wushouer, Luwen Shi. Trends of consumption and expenditure of antibacterial traditional Chinese medicine in secondary and tertiary hospitals in China: an analysis of pharmaceutical sales data, 2011–2015[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(4): 298-307.

图/表 3

Figure 1. Total AeTCM consumption and expenditure in sample hospitals in China, 2011–2015. AeTCM: antibacterial-effect traditional Chinese medicine.

Table 1. AeTCM consumption and expenditure in sample hospitals in China, 2011 and 2015.

Figure 2. Oral and parenteral AeTCM consumption and expenditure in sample hospitals, 2011–2015. AeTCM: antibacterial-effect traditional Chinese medicine.

参考文献 32

[1]	WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. This article can be found online at https://apps.who.int/iris/bitstream/handle/10665/277359/9789241514880-eng.pdf?ua=1.
[2]	McDonnell, L.; Armstrong, D.; Ashworth, M.; Dregan, A.; Malik, U.; White, P. National disparities in the relationship between antimicrobial resistance and antimicrobial consumption in Europe: an observational study in 29 countries. J. Antimicrob. Chemother. 2017, 72, 3199–3204.
[3]	Wushouer, H.; Zhang, Z.X.; Wang, J.H.; Ji, P.; Zhu, Q.F.; Aishan, R.; Shi, L.W. Trends and relationship between antimicrobial resistance and antibiotic use in Xinjiang Uyghur Autonomous Region, China: Based on a 3 year surveillance data, 2014-2016. J. Infect. Public Heal. 2018, 11, 339–346.
[4]	Xiao, Y.; Li, L. Legislation of clinical antibiotic use in China. Lancet Infect. Dis. 2013, 13, 189–191.
[5]	Xiao, Y.H. Antimicrobial stewardship in China: systems, actions and future strategies. Clin. Infect. Dis. 2018, 67, S135–S141.
[6]	Ji, H.F.; Li, X.J.; Zhang, H.Y. Natural products and drug discovery. EMBO Rep. 2009, 10, 194–200.
[7]	Li, C.Y.; Wang, P.; Zhang, L.; Li, M.; Lei, X.; Liu, S.; Feng, Z.Q.; Yao, Y.M.; Chang, B.; Liu, B.S.; Shang, H.C. Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: a meta-analysis of randomized controlled trials. J. Ethnopharmacol. 2018, 224, 512–521.
[8]	Fan, X.; Li, N.; Wang, X.; Zhang, J.; Xu, M.; Liu, X.; Wang, B. Protective immune mechanisms of Yifei Tongluo, a Chinese herb formulation, in the treatment of mycobacterial infection. PLoS One. 2018, 13, e0203678.
[9]	Zhang, W.; Wang, B.; Li, Z. Prevention of traditional Chinese medicine Gubiao Pixie prescription for nosocomial infection in elderly population. Chin. Crit. Care Med. 2017, 29, 469–472.
[10]	Ma, Y.X.; Chen, M.; Guo, Y.L.; Liu, J.; Chen, W.T.; Guan, M.Y.; Wang, Y.; Zhao, X.H.; Wang, X.; Li, H.Y.; Meng, L.X.; Wen, Y.L.; Wang, Y.G. Prevention and treatment of infectious diseases by traditional Chinese medicine: a commentary. APMIS. 2019, 127, 372–384.
[11]	Shi, Z.F.; Zhao, C.; Hu, J.Y.; Dai, Q.Q.; Guan, M.K.; Zhong, C.M.; Tian, G.H.; Shang, H.C. The application of traditional Chinese medicine injection on patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. Evid. Based Complement. Altern. Med. 2020, 2020, 3834128.
[12]	Gao, G.Y.; Leung, S.W.; Jia, Y.L. Serious concerns about the RCT study quality of traditional Chinese medicine injections for treating cardiovascular diseases and COVID-19. Cardiovasc. Drugs Ther. 2021, 35, 191–193.
[13]	Tan, L.; Li, M.; Lin, Y. Safety concerns of traditional Chinese medicine injections used in Chinese children. Evid. Based Complement. Altern. Med. 2019, 2019, 8310368.
[14]	Ji, K.M.; Chen, J.J.; Li, M.; Liu, Z.G.; Xia, L.X.; Wang, C.B.; Zhan, Z.K.; Wu, X.L. Comments on serious anaphylaxis caused by nine Chinese herbal injections used to treat common colds and upper respiratory tract infections. Regul. Toxicol. Pharmacol. 2009, 55, 134–138.
[15]	Wushouer, H.; Tian, Y.; Guan, X.D.; Han, S.; Shi, L.W. Trends and patterns of antibiotic consumption in China’s tertiary hospitals: Based on a 5 year surveillance with sales records, 2011-2015. PLoS One. 2017, 12, e0190314.
[16]	Lin, H.; Dyar, O.J.; Rosales-Klintz, S.; Zhang, J.Z.; Tomson, G.; Hao, M.; Stålsby Lundborg, C. Trends and patterns of antibiotic consumption in Shanghai municipality, China: a 6 year surveillance with sales records, 2009-14. J. Antimicrob. Chemother. 2016, 71, 1723–1729.
[17]	Chen, J.Y.; Min, R.; Wang, H.; Zhao, S.W.; Li, H.M.; Fang, P.Q. Trends and drivers of inpatient antibiotic consumption among 89 China tertiary general hospitals from 2011Q1 to 2015Q4. Biomed. Res. Int. 2018, 2018, 1–7.
[18]	Wang, Y.; Chao, E.; Wang, G. Guideline for Clinical Application of Chinese Patent Medicine - Infectious Diseases. Beijing: China Press of Traditional Chinese Medicine. 2015.
[19]	National Health and Family Planning Commission of People’s Republic of China. China Health Statistics Yearbook. Beijing: Peking Union Medical College Press. 2012.
[20]	China Statistical Yearbook 2011-2015. This article can be found online at http://www.stats.gov.cn/english/Statisticaldata/AnnualData/.
[21]	WHOCC-ATC/DDD Index. This article can be found online at https://www.whocc.no/atc_ddd_index/.
[22]	The Central Bank of the People’s Republic of China. This article can be found online at http://www.pbc.gov.cn/en/3688006/index.html.
[23]	National Data. This article can be found online at http://data.stats.gov.cn/english/.
[24]	Fujian Provincial Health Commission. Notification on the task of controlling medical expenses in 2011. This article can be found online at http://wjw.fujian.gov.cn/xxgk/zfxxgkzl/zfxxgkml/wszh/zdwssjhd/201105/t20110506_2336896.htm.
[25]	Zhejiang Provincial Health Commission. Guidance on strengthening the control of medical expenses in medical institutions. This article can be found online at http://www.zjwjw.gov.cn/art/2011/12/5/art_1202376_ 3462709.html.
[26]	Cai, Y.; Zhang, Q.; Fu, Y.; Li, L.; Zhao, N.; Lu, A.; Liu, Q.; Jiang, M. Effectiveness of Chinese herbal medicine combined with antibiotics for extensively drug-resistant enterobacteria and nonfermentative bacteria infection: real-life experience in a retrospective cohort. Biomed. Res. Int. 2017, 2017, 2897045.
[27]	Xu, H.R.; Li, M.; Wang, C.X.; Yin, R.Y.; Ma, J.; Wang, M.Z.; Tan, Q.M.; Jiang, L.D.; Cheng, M.; Chen, X.H.; Zhang, L.S.; Su, H.P.; Hao, R.F.; Jiao, Y.; Wang, C.H.; Wei, H.L.; Feng, C.L.; Luo, H.; Zhou, P.G. Evaluation on clinical efficacy of Fuzheng Jiedu Huayu Decoction combined with antibiotics in the treatment of pneumonia in the elderly - A multi-center, double-blind, parallel, randomized controlled trial. Complement. Ther. Med. 2018, 37, 127–132.
[28]	Tsai, C.C.; Lin, C.S.; Hsu, C.R.; Chang, C.M.; Chang, I.W.; Lin, L.W.; Hung, C.H.; Wang, J.L. Using the Chinese herb Scutellaria barbata against extensively drug-resistant Acinetobacter baumannii infections: in vitro and in vivo studies. BMC Complement. Altern. Med. 2018, 18, 96.
[29]	Chen, X.L.; Shang, F.; Meng, Y.J.; Li, L.; Cui, Y.M.; Zhang, M.; Qi, K.Z.; Xue, T. Ethanol extract of Sanguisorba officinalis L. inhibits biofilm formation of methicillin-resistant Staphylococcus aureus in an Ica-dependent manner. J. Dairy Sci. 2015, 98, 8486–8491.
[30]	Tan, X.J.; Yang, D.T.; Yang, G.X.; Chen, J.H.; Dong, W.; Shi, J.S.; Jia, A.Q. The investigation of inhibiting quorum sensing and methicillin-resistant Staphylococcus aureus biofilm formation from Liriodendron hybrid. Pak. J. Pharm. Sci. 2015, 28, 903–908.
[31]	Kuok, C.F.; Hoi, S.O.; Hoi, C.F.; Chan, C.H.; Fong, I.H.; Ngok, C.K.; Meng, L.R.; Fong, P. Synergistic antibacterial effects of herbal extracts and antibiotics on methicillin-resistant Staphylococcus aureus: a computational and experimental study. Exp. Biol. Med. (Maywood). 2017, 242, 731–743.
[32]	Han, F.; Xing, R.H.; Chen, L.Q.; Chen, L.; Xiong, W.; Yang, M.; Zhao, Z.D. Research progress of anti-drug resistance in traditional Chinese medicine. China J. Chin. Mater. Med. 2016, 41, 813–817.

中国二级和三级医院具有抗菌效果的中成药使用及费用变化趋势: 2011–2015年药品采购数据分析

Trends of consumption and expenditure of antibacterial traditional Chinese medicine in secondary and tertiary hospitals in China: an analysis of pharmaceutical sales data, 2011–2015

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 32

相关文章 2

编辑推荐

Metrics

本文评价

[1]	林洁莹, 刘京京, 齐亚宁, 王春明. 含吗啡中成药的滥用风险研究[J]. 中国药学(英文版), 2017, 26(2): 139-146.
[2]	朱愿超, 胡永芳, 杨莉萍, 胡欣. 临床药师干预对甲状腺手术围术期预防应用抗菌药物的影响[J]. 中国药学(英文版), 2015, 24(9): 617-624.